sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscov
longitudin
crosssect
studi
determin
preval
viru
bodili
excret
time
seroconvers
discharg
patient
sar
conjunctiv
throat
stool
urin
specimen
collect
weekli
patient
test
sarscov
rna
realtim
polymeras
chain
reaction
serum
sampl
collect
weekli
test
sarscov
antibodi
indirect
enzym
immunoassay
immunofluoresc
assay
total
conjunctiv
throat
swab
stool
urin
specimen
analyz
five
patient
posit
stool
sampl
collect
week
two
patient
seroconvert
week
other
seroposit
first
serum
sampl
collect
studi
patient
continu
shed
viral
rna
stool
sampl
week
ill
seroconvers
occur
week
ill
ever
acut
respiratori
syndrom
sar
newlydefin
condit
identifi
march
caus
novel
sarsassoci
coronaviru
sarscov
believ
origin
guangdong
provinc
china
subsequ
spread
citi
countri
august
total
countri
report
case
sar
countri
local
transmiss
approxim
case
report
least
death
singapor
index
casepati
woman
admit
hospit
atyp
pneumonia
march
return
trip
hong
kong
februari
addit
case
identifi
death
date
onset
ill
last
patient
may
role
bodi
fluid
transmiss
potenti
transmiss
convalesc
remain
undefin
hong
kong
exampl
faulti
sewag
work
residenti
block
deem
caus
major
outbreak
residenti
estat
excret
viru
rna
bodili
fluid
also
report
convalesc
phase
despit
patient
appar
clinic
recoveri
detect
sarscov
excret
bodili
fluid
would
thu
substanti
implic
infect
control
measur
recov
patient
return
commun
relationship
potenti
viru
secret
seroconvers
also
undefin
optim
time
test
seroconvers
seroconvers
suggest
occur
mean
day
ill
recent
avail
laboratori
test
detect
antibodi
sarscov
provid
mean
answer
clinic
question
longitudin
crosssect
studi
design
studi
preval
viru
durat
viral
shed
bodili
excret
stool
urin
throat
secret
conjunctiv
tear
use
nucleic
acid
amplif
test
sampl
patient
recent
recov
sar
also
sought
determin
factor
viral
shed
time
seroconvers
patient
recov
sar
patient
studi
recruit
tan
patient
identifi
exist
patient
registri
maintain
hospit
select
criteria
diagnosi
sar
base
current
world
health
organ
recommend
discharg
patient
patient
recruit
studi
anytim
day
discharg
day
discharg
discharg
criteria
base
exist
recommend
studi
endpoint
collect
arbitrarili
set
day
discharg
given
estim
hospit
stay
patient
studi
design
would
allow
sampl
day
ill
initi
studi
design
one
report
show
viral
rna
stool
sampl
convalescentphas
patient
day
ill
collect
specimen
day
appear
suffici
dedic
team
four
doctor
collect
weekli
specimen
throat
conjunctiva
consent
patient
fresh
specimen
midstream
urin
stool
blood
collect
concurr
steril
specimen
bottl
steril
swab
use
collect
throat
secret
fornic
back
throat
spatula
use
depress
tongu
procedur
swab
immedi
place
bottl
contain
hank
viral
transport
medium
use
steril
swab
conjunctiva
one
lower
eyelid
swab
one
brush
swab
rotat
conjunctiva
lower
eyelid
swab
similarli
swab
immedi
place
bottl
contain
hank
viral
transport
medium
midstream
urin
collect
steril
urin
contain
stool
specimen
collect
spatula
steril
stool
contain
accept
urin
stool
specimen
deliv
within
hour
collect
nine
millilit
blood
collect
tube
gel
serum
separ
kept
specimen
upon
receipt
except
blood
kept
process
weekli
collect
specimen
repeat
day
discharg
inform
demograph
clinic
cours
collect
laboratori
test
perform
depart
patholog
singapor
gener
hospit
revers
transcriptionpolymeras
chain
reaction
rtpcr
perform
conjunctiv
throat
stool
urin
specimen
realart
hpacoronaviru
rtpcr
kit
artu
gmbh
hamburg
germani
roch
lightcycl
roch
diagnost
corpor
indianapoli
realtim
pcr
instrument
assay
target
polymeras
gene
sarscov
posit
result
verifi
two
primer
pair
also
target
polymeras
gene
sarscov
first
primer
design
genom
institut
singapor
second
cor
primer
govern
viru
unit
hong
kong
sens
cac
cgt
ttc
tac
agg
tta
gct
aac
ga
antisens
aaa
tgt
tta
cgc
agg
taa
gcg
taa
aa
detect
limit
set
specimen
serum
specimen
test
total
virusspecif
antibodi
indirect
enzym
immunoassay
eia
sarscov
lysat
antigen
posit
serum
sampl
retest
immunoglobulin
ig
g
immunofluoresc
assay
ifa
sarscovinfect
vero
cell
spot
onto
microscop
slide
recruit
patient
select
basi
number
day
patient
discharg
hospit
analysi
date
convert
day
ill
subsequ
week
ill
determin
date
onset
ill
onset
ill
defin
day
onset
fever
exampl
specimen
collect
day
ill
thu
group
week
onset
ill
statist
analys
perform
spss
window
releas
spss
inc
chicago
il
categor
variabl
analyz
chisquar
test
student
test
use
analyz
continu
variabl
total
patient
met
select
criteria
patient
consent
studi
patient
withdrew
first
collect
mean
age
consent
patient
year
rang
year
men
mean
age
sar
patient
singapor
year
rang
year
male
patient
studi
recruit
week
ill
median
week
figur
patient
recruit
week
ill
ten
particip
coexist
condit
diabet
mellitu
hypertens
asthma
four
histori
previou
intens
care
admiss
hospit
stay
six
histori
steroid
treatment
defin
prior
use
hydrocortison
prednisolon
dexamethason
puls
methylprednisolon
regardless
dosag
frequenc
ribavirin
use
treatment
patient
sinc
interim
analysi
specimen
indic
posit
yield
day
discharg
decis
made
stop
subsequ
collect
day
discharg
specimen
alreadi
collect
process
total
conjunctiv
specimen
throat
swab
specimen
stool
specimen
urin
specimen
blood
specimen
avail
analysi
averag
specimen
taken
per
patient
rang
patient
least
one
specimen
type
taken
specimen
collect
rtpcr
test
taken
week
ill
mean
week
standard
deviat
sd
specimen
throat
conjunctiva
urin
neg
sarscov
rtpcr
six
stool
specimen
five
patient
posit
three
rtpcr
assay
figur
relev
clinic
histori
laboratori
data
patient
summar
tabl
five
patient
posit
viral
rna
stool
specimen
mean
age
year
two
five
patient
requir
supplement
oxygen
patient
admit
intens
care
mean
peak
lactat
dehydrogenas
ldh
ul
patient
stool
sampl
neg
sarscov
rna
mean
age
year
requir
supplement
oxygen
previous
admit
intens
care
mean
peak
ldh
patient
without
rna
detect
stool
sampl
ul
age
prior
supplement
oxygen
use
peak
ldh
statist
differ
two
group
patient
provid
one
sampl
withdrew
studi
immedi
thereaft
posit
sarscov
rtpcr
week
ill
subsequ
specimen
avail
analysi
three
stool
specimen
taken
patient
week
ill
specimen
taken
week
posit
patient
provid
two
stool
specimen
week
posit
sampl
taken
week
fewer
copi
per
reaction
rtpcr
compar
taken
week
sampl
request
physician
outsid
studi
collect
week
ill
test
neg
rtpcr
patient
provid
one
sampl
posit
week
ill
subsequ
specimen
avail
five
patient
posit
sarscov
detect
rtpcr
stool
sampl
one
patient
histori
prior
steroid
treatment
sar
ill
mention
earlier
patient
provid
one
sampl
withdraw
studi
five
patient
receiv
steroid
treatment
hospit
none
sarscov
detect
rtpcr
patient
recruit
week
ill
patient
receiv
ribavirin
two
sampl
posit
sarscov
rna
comparison
patient
receiv
ribavirin
sarscov
detect
rtpcr
differ
signific
diarrhea
report
studi
patient
one
sampl
posit
sarscov
rna
remain
rnaposit
sampl
patient
report
diarrhea
symptom
hospit
stay
ten
particip
histori
chronic
ill
three
asthma
five
hypertens
one
diabet
mellitu
type
one
addit
patient
diabet
mellitu
type
hypertens
sampl
collect
patient
week
ill
mean
week
sd
none
patient
sarscov
viral
rna
detect
studi
total
specimen
patient
avail
analysi
specimen
posit
eia
except
two
specimen
taken
week
patient
respect
posit
result
corrobor
posit
ifa
except
sampl
patient
neg
ifa
week
ill
next
sampl
taken
week
posit
eia
ifa
result
first
sampl
blood
taken
serolog
test
plot
respect
week
ill
figur
patient
whose
initi
result
neg
serolog
test
result
becam
posit
subsequ
week
test
week
respect
sarscov
detect
mucos
secret
excreta
affect
decis
discharg
patient
detect
sarscov
would
greater
import
detect
respiratori
tract
throat
swab
tear
conjunctiv
swab
test
sampl
patient
discharg
hospit
access
patient
deem
clinic
fit
return
commun
posit
rtpcr
result
patient
would
import
compar
result
patient
recov
hospit
weekli
test
conduct
assess
risk
use
molecular
diagnost
method
first
longitudin
crosssect
studi
viral
shed
convalescentphas
sar
patient
perform
weekli
test
optim
time
seroconvers
recov
patient
could
determin
inform
assist
clinician
plan
reason
time
serolog
test
patient
suspect
case
sar
studi
viral
nucleic
acid
sarscov
detect
stool
sampl
find
infrequ
patient
posit
sampl
week
ill
figur
one
patient
still
detect
viral
rna
week
ill
none
patient
viral
nucleic
acid
sarscov
detect
respiratori
urin
conjunctiv
sampl
detect
viral
nucleic
acid
sarscov
stool
sampl
recov
patient
report
sampl
posit
day
studi
drosten
et
al
day
studi
leung
et
al
drosten
et
al
studi
involv
two
patient
viral
rna
detect
convalesc
phase
day
ill
leung
et
al
studi
author
examin
gastrointestin
manifest
patient
sar
admit
local
hospit
overal
detect
rate
sarscov
rna
stool
specimen
whether
sampl
taken
acut
phase
convalesc
phase
unknown
author
observ
one
patient
viral
rna
detect
stool
sampl
day
symptom
onset
clinic
inform
avail
patient
later
studi
chan
et
al
report
viral
rna
detect
stool
sampl
submit
week
ill
last
posit
sampl
detect
week
ill
studi
respiratori
sampl
tracheal
aspir
nasopharyng
aspir
throat
swab
throat
wash
nasal
swab
pool
throat
nasal
swab
detect
week
ill
shed
viru
prolong
period
arbitrarili
defin
week
onset
symptom
sampl
collect
still
critic
ill
studi
differ
cohort
patient
compar
patient
discharg
compar
shorter
milder
ill
determin
whether
posit
carriag
persist
critic
ill
patient
chan
et
al
studi
discharg
would
benefici
sarscov
isol
studi
unabl
assess
posit
stool
sampl
infecti
howev
chan
et
al
studi
sampl
submit
stool
isol
posit
week
ill
studi
leung
et
al
viru
isol
stool
sampl
find
similar
experi
singapor
laboratori
primari
center
sarscov
isol
epidem
success
isol
virus
stool
sampl
stool
sampl
posit
sarscov
convalescentphas
sar
patient
would
probabl
minim
effect
public
secondari
sar
case
convalescentphas
sar
patient
discharg
hospit
report
howev
still
recommend
caution
especi
pediatr
patient
adult
requir
full
nurs
aid
sinc
sarscov
surviv
least
day
room
temperatur
greater
sever
ill
excret
viru
would
like
prolong
identifi
sever
ill
histori
supplement
oxygen
use
admiss
intens
care
high
peak
ldh
peak
ldh
identifi
along
advanc
age
predictor
advers
outcom
hong
kong
howev
studi
patient
age
supplement
oxygen
use
peak
ldh
statist
differ
posit
stool
sampl
neg
stool
sampl
sampl
four
patient
previou
histori
intens
care
admiss
neg
sarscov
rna
rtpcr
find
suggest
durat
viral
rna
excret
convalesc
phase
may
sole
determin
sever
ill
howev
number
intens
care
patient
studi
small
six
patient
studi
receiv
steroid
treatment
compar
sar
cohort
singapor
stool
sampl
one
patient
posit
rna
possibl
explan
find
includ
small
number
treat
steroid
studi
fact
stool
sampl
neg
rna
steroid
recruit
late
ill
week
sarscov
viral
rna
detect
stool
sampl
patient
chronic
ill
sarscov
viral
rna
histori
chronic
ill
possibl
explan
recruit
patient
late
ill
use
ribavirin
appear
reduc
detect
rate
viral
rna
stool
sampl
find
concur
observ
vitro
studi
retrospect
cohort
studi
suggest
ribavirin
effect
sarscov
separ
studi
leong
et
al
show
ribavirin
confer
surviv
benefit
patient
sar
activ
replic
sarscov
report
small
larg
intestin
diarrhea
associ
higher
proport
patient
sarscovposit
stool
sampl
increas
intestin
motil
caus
diarrhea
might
lessen
viral
load
gastrointestin
tract
patient
symptom
hong
kong
igg
seroconvers
detect
day
ill
mean
day
ninetythre
percent
patient
seroconvert
day
week
ill
part
protocol
patient
receiv
steroid
intraven
hydrocortison
oral
prednisolon
puls
methylprednisolon
diagnosi
sar
steroid
appear
affect
seroconvers
rate
toronto
group
report
similar
result
seroposit
rate
day
ill
beyond
two
patient
demonstr
posit
eia
result
initi
specimen
collect
result
expect
sinc
patient
recruit
week
ill
week
ill
patient
posit
serolog
result
patient
demonstr
seroconvers
week
ill
respect
find
congruent
hong
kong
studi
therefor
diagnost
role
serolog
test
limit
acut
phase
ill
steroid
use
infrequ
patient
studi
patient
receiv
intraven
hydrocortison
hospit
stay
five
particip
receiv
steroid
hospit
stay
detect
antibodi
first
specimen
collect
perform
week
four
patient
week
one
patient
patient
seroconvert
week
prior
steroid
use
suggest
serolog
respons
mute
use
steroid
two
patient
seroconvert
sequenti
weekli
collect
ribavirin
symptom
diarrhea
hospit
stay
studi
limit
factor
design
studi
crosssect
allow
us
accur
determin
seroconvers
occur
viral
rna
ceas
detect
patient
sever
ill
intens
care
patient
declin
particip
return
hospit
weekli
basi
specimen
sampl
also
difficult
patient
substanti
sequela
infect
even
recruit
particip
alreadi
later
half
convalesc
patient
sever
ill
would
longer
hospit
stay
time
discharg
would
beyond
week
ill
studi
particip
earli
phase
recoveri
outbreak
singapor
alreadi
control
studi
commenc
end
april
limit
number
elig
particip
earli
convalesc
phase
detect
sarscov
rna
uncommon
recov
patient
discharg
hospit
studi
rtpcr
determin
patient
continu
shed
viral
rna
stool
sampl
week
ill
seroconvers
occur
week
ill
although
seroconvers
may
still
occur
week
ill
excret
viral
rna
seroconvers
appear
relat
age
underli
condit
diarrhea
prior
steroid
ribavirin
use
sever
ill
secondari
case
infect
occur
among
convalescentphas
patient
